Table 1.
Baseline characteristics of patients in TO and TA groups.
| Characteristic | TO (n = 64) | TA (n = 32) | p |
|---|---|---|---|
| Age, mean ± SD | 53.4 ± 12.4 | 53.6 ± 13.6 | 0.960 |
| Gender, n (%) | 0.172 | ||
| Female | 5 (7.8%) | 6 (18.8%) | |
| Male | 59 (92.2%) | 26 (81.2%) | |
| BCLC stage, n (%) | 1.000 | ||
| B | 32 (50.0%) | 16 (50.0%) | |
| C | 32 (50.0%) | 16 (50.0%) | |
| CNLC stage, n (%) | 0.912 | ||
| IIb | 32 (50.0%) | 16 (50.0%) | |
| IIIa | 24 (37.5%) | 11 (34.4%) | |
| IIIb | 8 (12.5%) | 5 (15.6%) | |
| Child-Pugh, n (%) | 0.636 | ||
| A | 54 (84.4%) | 25 (78.1%) | |
| B | 10 (15.6%) | 7 (21.9%) | |
| ALBI grade, n (%) | 0.206 | ||
| 1 | 6 (9.4%) | 6 (18.8%) | |
| 2 | 58 (90.6%) | 26 (81.2%) | |
| Performance status, n (%) | 0.527 | ||
| 0 | 57 (89.1%) | 27 (84.4%) | |
| 1 | 7 (10.9%) | 5 (15.6%) | |
| Tumor number, n (%) | 1.000 | ||
| Multiple | 55 (85.9%) | 28 (87.5%) | |
| Solitary | 9 (14.1%) | 4 (12.5%) | |
| Largest size (cm), median (Q1, Q3) | 11.5 (8.3, 14.3) | 11.5 (8.7, 13.1) | 0.756 |
| AFP, n (%) | 1.000 | ||
| <400 | 25 (39.1%) | 13 (40.6%) | |
| ≥400 | 39 (60.9%) | 19 (59.4%) | |
| PVTT, n (%) | 0.827 | ||
| Absence | 35 (54.7%) | 19 (59.4%) | |
| Presence | 29 (45.3%) | 13 (40.6%) | |
| Extrahepatic spread, n (%) | 0.755 | ||
| No | 56 (87.5%) | 27 (84.4%) | |
| Yes | 8 (12.5%) | 5 (15.6%) |
TO, TACE only; TA, TACE combined with anlotinib; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer; CNLC, China Liver Cancer Staging; ALBI, albumin–bilirubin; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombus.